Previous 10 | Next 10 |
Reata Pharmaceuticals (NASDAQ:RETA) is scheduled to announce Q1 earnings results on Thursday, May 6th, before market open.The consensus EPS Estimate is -$1.73 (-94.4% Y/Y) and the consensus Revenue Estimate is $1.43M (+5.9% Y/Y).Over the last 2 years, RETA has beaten EPS estimates 38% of the ...
[[ACIW]], [[ADNT]], [[AES]], [[AHCO]], [[ALE]], [[APTV]], [[ARW]], [[AVYA]], [[AZUL]], [[BDX]], [[BIP]], [[BKI]], [[BLD]], [[BLDR]], [[BLL]], [[BUD]], [[BV]], [[CAH]], [[CARS]], [[CNP]], [[COMM]], [[CORE]], [[CWEN]], [[DEN]], [[DLX]], [[DOCN]], [[ECOM]], [[EPAM]], [[EPC]], [[EPZM]], [[EVOP]],...
PLANO, Texas, May 03, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will present and hold 1x1 meetings at the follow...
PLANO, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on i...
Reata Pharmaceuticals (RETA) announces that the U.S. FDA has accepted its New Drug Application for bardoxolone methyl for the treatment of patients with chronic kidney disease (“CKD”) caused by Alport syndrome for review and has set an action date of February 25, 2022.The h...
Approximately 30,000-60,000 Patients in the United States Are Affected With Alport Syndrome, a Life-Threatening Disease With No Approved Therapies Application Assigned a P DUFA Date of February 25, 2022 If Approved, Bardoxolone Would Become the ...
Barclays is bullish on shares of Reata Pharmaceuticals (RETA) as the FDA could accept an NDA for its lead program, bardoloxone for chronic kidney disease ("CKD"), by the end of the month or in early May.Reata submitted the NDA for bardoloxone for CKD caused by Alport syndrome in Mar...
PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointments of Christy J. Oliger and Shamim Ruff to its B...
PLANO, Texas, March 29, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for bardoxolone meth...
Design Therapeutics has filed proposed terms for a $228 million IPO. The firm is developing treatments for Friedreich ataxia and myotonic dystrophy. DSGN is still at a preclinical stage of development and is seeking a high valuation at IPO; the IPO may be more suited to institutio...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...